STAT+: Pharmalittle: Pfizer projects lower revenue from Covid-19 products; Medicare eyes policy for paying less for accelerated-approval drugs
A Medicare official hinted the program might test a policy of paying less for drugs that receive accelerated approvals than for medicines granted traditional approvals.
by Ed Silverman
Feb 01, 2023
1 minute
Top of the morning to you. The middle of the week is upon us and, since you made it this far, why not
You’re reading a preview, subscribe to read more.
Start your free 30 days